Related Experiment Video

Updated: Sep 28, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.1K

Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis

Teruhiko Imamura1, Toshihide Izumida1, Makiko Nakamura1

  • 1Second Department of Internal Medicine, University of Toyama.

International Heart Journal
|March 31, 2022
PubMed

Insights

Neurohormonal blockers may improve cardiac reverse remodeling in patients with systolic heart failure and cardiac amyloidosis. This small study suggests potential benefits, but larger trials are needed to confirm these findings for heart failure treatment.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Cardiac Amyloidosis Research

Background:

  • Guideline-directed medical therapy for systolic heart failure often includes neurohormonal blockers.
  • The efficacy of neurohormonal blockers in patients with co-existing cardiac amyloidosis is not well-established.
  • Cardiac amyloidosis presents unique challenges in heart failure management.

Purpose of the Study:

  • To investigate the potential impact of neurohormonal blockers on cardiac reverse remodeling in patients with systolic heart failure and cardiac amyloidosis.
  • To explore the clinical outcomes associated with neurohormonal blocker use in this specific patient cohort.

Main Methods:

  • Retrospective case review of three patients diagnosed with systolic heart failure and cardiac amyloidosis.
  • Analysis of cardiac function and reverse remodeling in patients who received neurohormonal blockers versus those who did not.

Main Results:

  • Two out of three patients who received neurohormonal blockers demonstrated cardiac reverse remodeling.
  • One patient not receiving neurohormonal blockers showed no significant change in cardiac function.
  • Preliminary evidence suggests a positive association between neurohormonal blockers and improved cardiac structure.

Conclusions:

  • Neurohormonal blockers may facilitate cardiac reverse remodeling and improve outcomes in patients with systolic heart failure and cardiac amyloidosis.
  • Further large-scale studies are warranted to validate the role of neurohormonal blockers in managing this complex patient group.
  • These findings highlight a potential therapeutic avenue for a challenging cardiovascular condition.

Keywords:
HemodynamicsTafamidis

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
540
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
52
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
26
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
44